OrthoPediatrics (NASDAQ:KIDS) Issues Earnings Results

OrthoPediatrics (NASDAQ:KIDS) posted its quarterly earnings data on Thursday. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02, FiscalAI reports. The company had revenue of $59.36 million during the quarter, compared to analysts’ expectations of $58.34 million. OrthoPediatrics had a negative net margin of 16.77% and a negative return on equity of 6.70%.

Here are the key takeaways from OrthoPediatrics’ conference call:

• Raised 2026 guidance to a revenue range of $263M–$267M (11%–13% growth), and reaffirmed ~$25M adjusted EBITDA with a goal of full-year free cash flow breakeven — management called this a sign of sustained execution.
• Early beta launches — including 3P Hip, VerteGlide, and TRAXIO — are generating strong demand; the company expects these products to drive higher ASPs, margin expansion, and improved capital efficiency as set deployments scale.
• OPSB (specialty bracing and clinics) grew >20% in Q1, with clinic expansion ahead of plan and a target of 27 territories by end of 2027, supporting both revenue and profitability upside.
• International revenue accelerated (>20% growth) and the business received full EU MDR approvals for key portfolios, enabling broader European commercialization and stabilizing LATAM through the Brazil distributor acquisition.
• While Q1 revenue was $59.4M (+13%) and adjusted EBITDA turned positive ($2.2M), the company still reported a GAAP net loss of $0.45/share, used $5M free cash flow in Q1, and is keeping guidance and set‑deployment conservative, which could limit near-term upside.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock traded up $0.42 during trading hours on Thursday, reaching $15.06. 242,989 shares of the company’s stock were exchanged, compared to its average volume of 149,142. OrthoPediatrics has a 1 year low of $14.42 and a 1 year high of $23.70. The company has a market capitalization of $386.89 million, a P/E ratio of -8.91 and a beta of 1.16. The business has a fifty day moving average of $16.73 and a two-hundred day moving average of $17.28. The company has a quick ratio of 2.65, a current ratio of 5.55 and a debt-to-equity ratio of 0.28.

Insider Transactions at OrthoPediatrics

In related news, General Counsel Daniel J. Gerritzen sold 8,614 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total value of $148,591.50. Following the completion of the sale, the general counsel owned 149,533 shares of the company’s stock, valued at approximately $2,579,444.25. This represents a 5.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gregory A. Odle sold 8,433 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $145,469.25. Following the completion of the sale, the insider directly owned 187,735 shares of the company’s stock, valued at $3,238,428.75. This represents a 4.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 58,171 shares of company stock valued at $1,003,450 in the last three months. 32.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On OrthoPediatrics

A number of hedge funds have recently modified their holdings of the company. Invesco Ltd. grew its holdings in shares of OrthoPediatrics by 14.5% in the fourth quarter. Invesco Ltd. now owns 39,002 shares of the company’s stock valued at $693,000 after purchasing an additional 4,925 shares during the period. XTX Topco Ltd purchased a new stake in shares of OrthoPediatrics in the fourth quarter valued at about $188,000. Tudor Investment Corp ET AL grew its holdings in shares of OrthoPediatrics by 59.3% in the fourth quarter. Tudor Investment Corp ET AL now owns 112,996 shares of the company’s stock valued at $2,007,000 after purchasing an additional 42,061 shares during the period. Millennium Management LLC grew its holdings in shares of OrthoPediatrics by 48.0% in the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after purchasing an additional 452,840 shares during the period. Finally, Engineers Gate Manager LP purchased a new stake in shares of OrthoPediatrics in the fourth quarter valued at about $226,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group set a $25.00 target price on shares of OrthoPediatrics in a report on Friday, April 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a report on Tuesday, April 21st. BTIG Research upped their target price on shares of OrthoPediatrics from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Truist Financial upped their target price on shares of OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a report on Monday, March 2nd. Finally, Wall Street Zen raised shares of OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.78.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.